Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
RecruitingObservational studyHealthy volunteers welcome
Who can join
All ages · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Currently using one or more topical glaucoma antihypertensives * Self-described symptoms of ocular surface discomfort * Xiidra is being prescribed as part of the subject's standard care Exclusion Criteria: * History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.), * current use of topical cyclosporine * current use of topical steroids * incisional ocular surgery within 6 months
About the study
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
What is being tested
- Xiidra (Lifitegrast ophthalmic solution) 5% (drug)
Sponsor: University of California, Los Angeles · Participants: 75 · Started: Apr 1, 2021
Contact the study team
- Benjamin B Bert, MD · Phone: 626-817-4701
- Mayra Raygoza · Phone: 16268174747
Official record on ClinicalTrials.gov — NCT04354545
Locations in the U.S.
| California | Doheny Eye Center UCLA, Fountain Valley |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.